Meta-analysis about Atrial Natriuretic Peptide (ANP)

Among the topics studied in physiology and aging, a hormone has been drawing attention from the scientificcommunity: the Atrial Natriuretic Peptide (ANP). The ANP, which is produced by the cardiac atria, hasdemonstrated decisive action in endocrine mechanisms of action inhibiting sodium reabsorption in nephrons,revealing a direct influence on physiological mechanisms linked to aging and chronic stress.The overall objectiveof this study was to assess and analyze scientific literature on the ANP in the Pubmed database from 2010 to2012. 30 articles were collected, verifying authorship and gender division of species, instruments and typesof research. The results showed that the research of multiple authorship appeared mostly with 99.1%, being51.8% of male authorship, 17.9% of female authorship and 29.5% of publications not identified. Researchwith only one author appears with 0.8% in total. As the types of species used, it was observed 50.3% of theworks with humans, 40% with animals and 6.7% mixed (animal / human). As to the instruments used, thebiochemical markers were the ones that stood out, with 30%, followed by label arterial pressure with 12, 2%,drugs, with 11.1% and microscopic studies with 10%. In the typology of research, biochemical research appearsfirst, with 33.3%, followed by research morphophysiological/biochemical research, with 30%, Physiological/ biochemical, with 26.7%, Physiological with 6.7% and Morphophysiological with 3.3%. We can concludethat the publications about the hormone ANP are still little explored when the focus is aging. In the analyzedpublications, there is important information about the physiological and biochemical role of ANP as well ason their molecular composition.

Serum erythropoietin and circulating BFU-E in patients with multiple myeloma and anaemia but without renal failure.

In 30 patients with multiple myeloma (MM) and mild to moderate anaemia (mean Hb 107 g/l, 95% confidence limit (CL) 102-113) but no evidence of renal failure (serum creatinine < 110 mumol/l), serum erythropoietin (EPO) showed significant inverse logarithmic correlation with the haemoglobin level (r = -0.57, p = 0.001). The observed/expected ratio of log-EPO in patients with MM (mean 0.96, CL 0.89-1.04) was similar to that of 119 subjects (mean 1.01, CL 0.96-1.05) with or without anaemia (mean Hb 116 g/L, CL 110-121) but without renal failure. The concentration of circulating erythroid progenitors (BFU-E) in 10 MM patients in plateau phase was significantly reduced (mean 0.70 x 10(5)/l of blood, CL 0.34-1.06) compared to that of 8 normal controls (mean 3.57, CL 1.60-5.55, p = 0.011) In vitro sensitivity of the BFU-E to EPO in the patients with MM was comparable to that of the normal controls. It appears that in MM there is an appropriate EPO response to anaemia but even in the plateau phase the number of circulating BFU-E is reduced, reflecting a degree of marrow failure. However, the progenitors are normally sensitive to EPO in such patients, and therapeutic doses of EPO may correct the anaemia by a pharmacological rather than a physiological effect.